Table 4. Univariate analysis of prognostic factors for overall survival and disease specific survival for patients included in the systematic review.
| Overall survival | Disease specific survival | |||||
|---|---|---|---|---|---|---|
| Unit risk ratio (95% CI) |
HR | p -Value | Unit risk ratio (95% CI) |
HR | p -Value | |
| Age (y) | 1.02 (1.003–1.043) | – | 0.0216 | 1.015 (0.994–1.037) | – | 0.148 |
| Male sex | – | 2.07 | 0.0753 | – | 3.506 | 0.0611 |
| AJCC T4 vs. T1–T3 stages | – | 2.81 | 0.0253 * | – | 3.566 | 0.0100 |
| Primary therapy | ||||||
| Surgery | – | 0.49 | 0.0808 | – | 0.481 | 0.084 |
| No surgery | – | – | ||||
| Adjuvant therapy | ||||||
| Yes | – | 0.6078 | 0.1726 | – | 0.694 | 0.351 |
| No | – | – | ||||
| Histologic subtype | ||||||
| Osteoblastic vs. chondroblastic | – | 1.88 | 0.436 | – | 8.04 | 0.066 |
| Fibroblastic vs. chondroblastic | – | 4.79 | 0.067 | – | 3.78 | 0.216 |
| Multiple vs. chondroblastic | – | 3.25 | 0.178 | – | 6.52 | 0.096 |
Abbreviations: CI, confidence interval; HZ, hazard ratio.